Focus: Ascendis Pharma is a public biotech company specializing in prodrug therapies across oncology, endocrinology, ophthalmology, neurology, and rare diseases. Founded in 2007 and headquartered in Palo Alto, CA, the company has achieved market validation with one launched product and a robust late-stage pipeline.
Profile data last refreshed 6h ago · AI intelligence enriched 6d ago
Stable — net -2 jobs in 30d
21 added, 23 removed. Backfill posture.
Ascendis offers solid early-to-mid stage biotech exposure with a validated platform and multiple near-term shots on goal, but recent workforce restructuring and modest hiring signal near-term uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
First and only approved CNP receptor agonist for achondroplasia, launched recently with 17+ years of patent protection providing long commercial runway.
Help build intelligence for Ascendis Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ascendis Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Polaryx Therapeutics, Inc. (PLYX) (CIK 0002075320) — PRESS RELEASE, DATED SEPTEMBER 1, 2026
PRESS RELEASE, DATED SEPTEMBER 1, 2026
8-K Filing: BIOMARIN PHARMACEUTICAL INC (BMRN) (CIK 0001048477) — EX-99.1
EX-99.1
8-K Filing: Crinetics Pharmaceuticals, Inc. (CRNX) (CIK 0001658247) — 8-K
8-K
Ascendis Pharma Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Ascendis Pharma Number of Employees 2026 | Employee Count & Headcount Data reveliolabs.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data Investing.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com - Investing.com Canada
Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com Investing.com Canada
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent 60-person headcount reduction in Palo Alto indicates active portfolio optimization and potential future restructuring if pipeline programs underperform.
Recent peer-reviewed publications with author affiliations at this company
Reframing the value of reserve antibiotics: how ultra-orphan reimbursement pathways could offer fair and equitable access to new antibiotics.
Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience.
+1 more
+2 more
+1 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo